Authors:
Luiza de Oliveira Martins
In 2014, the Bill and Melinda Gates Foundation announced a generous endowment of over 20 million dollars to a startup called Microchips Biotech [1]. The money was meant to support the research and development of the startup's flagship product: a wireless, smart birth-control implant that could be turned on and off through an app. Each implant was designed to remain active for 16 years—a significant part of one's entire fertile life—as opposed to the three years of currently available contraceptives. Additionally, the implant could collect a wealth of data about patients, ostensibly to provide tailored healthcare solutions. Insights…
You must be a member of SIGCHI, a subscriber to ACM's Digital Library, or an interactions subscriber to read the full text of this article.
GET ACCESS
Join ACM SIGCHIIn addition to all of the professional benefits of being a SIGCHI member, members get full access to interactions online content and receive the print version of the magazine bimonthly.
Subscribe to the ACM Digital Library
Get access to all interactions content online and the entire archive of ACM publications dating back to 1954. (Please check with your institution to see if it already has a subscription.)
Subscribe to interactions
Get full access to interactions online content and receive the print version of the magazine bimonthly.
